Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind phase II trial of MK-0594 (serlopitant) in alcohol dependence
2008-004686-26Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing MK-0594 with Placebo (2 arms). Primary endpoints: Maintained absence of heavy drinking (Weeks 3–12) and Maintained abstinence (Weeks 3–12). Started Sep 2008; status: completed.
02
Drugs
serlopitant
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2008-004686-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004686-26.